An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

June 21, 2016

Primary Completion Date

October 12, 2021

Study Completion Date

October 12, 2021

Conditions
Malignant Solid Tumor
Interventions
BIOLOGICAL

BMS-986179

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

rHuPH20

Specified dose on specified days

Trial Locations (24)

2010

Local Institution - 0017, Sydney

2031

Local Institution - 0019, Randwick

3004

Local Institution - 0018, Melbourne

10032

Local Institution - 0005, New York

13273

Local Institution - 0033, Marseille

13385

Local Institution - 0021, Marseille

14263

Local Institution - 0023, Buffalo

15232

Local Institution - 0020, Pittsburgh

21287

Local Institution - 0001, Baltimore

31059

Local Institution - 0008, Toulouse

37203

Local Institution - 0004, Nashville

60611

Local Institution - 0028, Chicago

75230

Local Institution - 0009, Dallas

79106

Local Institution - 0016, Freiburg im Breisgau

80131

Local Institution - 0012, Napoli

81675

Local Institution - 0015, Munich

94805

Local Institution - 0007, Villejuif

02215

Local Institution - 0022, Boston

K1H 8L6

Local Institution - 0003, Ottawa

M5G 1Z5

Local Institution - 0002, Toronto

H2X 3E4

Local Institution - 0024, Montreal

H3T 1E2

Local Institution - 0014, Montreal

Padova

Local Institution - 0013, Padua

1066 CX

Local Institution - 0006, Amsterdam

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY